Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Pancreatic Cancer
About this trial
This is an interventional treatment trial for Pancreatic Cancer focused on measuring rubitecan, Orathecin, 9-nitrocamptothecin, gemcitabine, Gemzar, pancreatic cancer, adenocarcinoma, RFS 2000
Eligibility Criteria
Inclusion Criteria: The patient is at least 18 years of age. The patient has histologically or cytologically confirmed, non-resectable, Stage II-IV primary adenocarcinoma of the pancreas. The patient has had a baseline computed tomography (CT) scan, or magnetic resonance imaging (MRI), to evaluate tumor(s) within 28 days prior to randomization. The patient has never been treated with prior chemotherapy, with the exception of low-dose 5-fluorouracil (5-FU) as a radiation sensitizer. The patient has sufficiently recovered from the effects of previous surgery (no less than 3 weeks prior to randomization), radiotherapy, and/or immunotherapy (no less than 4 weeks prior to randomization). The patient's estimated life expectancy is at least 12 weeks. The patient has a Karnofsky Performance Status between 50 and 100. The patient has adequate bone marrow function. The patient has adequate hepatic and renal function. Exclusion Criteria: The patient has any active, uncontrolled infection requiring antibiotics. The patient has any serious, uncontrolled concomitant systemic disorder. The patient has surgery scheduled within 8 weeks following initiation of treatment. The patient is pregnant or nursing. The patient is not capable of consistent oral intake of at least 3 L/day of fluid and/or requires constant intravenous (IV) hydration or frequent tube feeding. The patient is receiving any investigational agent(s) or has been a participant in a clinical trial within the last 30 days.
Sites / Locations
- Compassionate Cancer Care Medical Group
- 11100 Warner Avenue, Ste. 200
- The Cancer Research & Prevention Center
- Mile High Oncology
- Norton Healthcare, Inc.
- Mary Bird Perkins Cancer Center
- Medical Oncology
- N. Mississippi Hematology & Oncology Associates
- Kansas City Cancer Center
- Cancer Research of Long Island
- Charleston Hematology Oncology, PA